Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD)

Chieh Hsin Lin, Hui Ting Yang, Ping Kun Chen, Shi Heng Wang, Hsien Yuan Lane

研究成果: 雜誌貢獻文章同行評審

21 引文 斯高帕斯(Scopus)


Objective: Behavioral and psychological symptoms of dementia (BPSD) are associated with poorer prognosis of dementia. A 24-week study demonstrated that sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, surpassed placebo in improving cognitive function in early-phase Alzheimer’s disease; however, benzoate did not excel placebo in another 6-week study on BPSD. The current study examined whether the precision medicine approach was able to identify specific individuals with BPSD who could benefit from benzoate treatment. Methods: In the randomized, double-blind, placebo-controlled, 6-week trial, 97 patients with BPSD were allocated to receive 250–1500 mg/day of sodium benzoate or placebo. Cognitive function was measured by the Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog) and behavioral and psychological symptoms were mainly measured by Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD). DAAO level, amino acids (L-serine, D-serine, L-alanine, and D-alanine, glycine), and two antioxidants (catalase, superoxide dismutase) were assayed in peripheral blood. Results: After benzoate treatment, DAAO inhibition was correlated with ADAS-cog decrease (p = 0.034), while baseline DAAO level was correlated with baseline BEHAVE-AD score. Multiple linear regression analyses showed that cognitive improvement after benzoate treatment was correlated with DAAO decrease, female gender, younger age, BMI, baseline BPSD severity, and antipsychotic use. Conclusion: The finding suggests that sodium benzoate may have potential to benefit cognitive function in a fraction of BPSD patients after 6 weeks of treatment. Of note, the precision medicine approach may be helpful for identifying individuals who could respond to benzoate. More studies are warranted to confirm the preliminary findings.

頁(從 - 到)509-518
期刊Neuropsychiatric Disease and Treatment
出版狀態已發佈 - 1月 1 2020

ASJC Scopus subject areas

  • 精神病學和心理健康
  • 生物精神病學


深入研究「Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD)」主題。共同形成了獨特的指紋。